Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia

Phase 2 Completed 124 enrolled H. Lundbeck A/S

RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to explore the efficacy, safety and cognitive properties of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia.

Timeline

Start: 2008-11
Primary completion: 2010-01
Completion: 2010-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Idalopirdine	Small molecule	60 mg	Oral

Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia

Summary

Timeline

Drugs

Indications